News Sanofi gives up on amlitelimab in atopic dermatitis Sanofi has stopped development of anti-OX40L drug amlitelimab in atopic dermatitis, a major blow to what was once viewed as a 'pipeline-in-a-product'.
News J&J's multiple myeloma duo aces phase 3 trial Two of Johnson & Johnson's multiple myeloma bispecifics, Tecvayli and Talvey, have dramatically improved survival when used as a second-line regimen.
News Lilly plans Q1 2027 filing for obesity triple retatrutide Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.
News Kaken details the data behind its PI3K inhibitor filing Kaken has revealed the data that supported its recent marketing application for serabelisib as a treatment for vascular malformations in Japan.
News Gilead, MSD share data on once-weekly oral HIV treatment Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
News Agios shares slide as it abandons sickle cell candidate Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in sickle cell disease.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.